Several brokerages have updated their recommendations and price targets on shares of Bristol-Myers Squibb (NYSE: BMY) in the last few weeks:

  • 8/10/2017 – Bristol-Myers Squibb was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $64.08 price target on the stock.
  • 8/9/2017 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $63.81 price target on the stock.
  • 8/9/2017 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $63.00 price target on the stock.
  • 7/31/2017 – Bristol-Myers Squibb was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/28/2017 – Bristol-Myers Squibb had its price target lowered by analysts at Leerink Swann from $66.00 to $61.00. They now have an “outperform” rating on the stock.
  • 7/27/2017 – Bristol-Myers Squibb was given a new $60.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 7/26/2017 – Bristol-Myers Squibb had its “underperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $47.00 price target on the stock, down previously from $51.00.
  • 7/26/2017 – Bristol-Myers Squibb was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $64.33 price target on the stock.
  • 7/25/2017 – Bristol-Myers Squibb was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $61.66 price target on the stock.
  • 7/17/2017 – Bristol-Myers Squibb was given a new $55.00 price target on by analysts at Deutsche Bank AG. They now have a “hold” rating on the stock.
  • 7/12/2017 – Bristol-Myers Squibb had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $63.00 price target on the stock.
  • 7/12/2017 – Bristol-Myers Squibb was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $62.23 price target on the stock.
  • 7/10/2017 – Bristol-Myers Squibb was given a new $65.00 price target on by analysts at Cowen and Company. They now have a “hold” rating on the stock.
  • 7/3/2017 – Bristol-Myers Squibb was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/27/2017 – Bristol-Myers Squibb was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/26/2017 – Bristol-Myers Squibb had its “outperform” rating reaffirmed by analysts at William Blair.

Shares of Bristol-Myers Squibb Company (NYSE:BMY) opened at 56.59 on Friday. The company has a market capitalization of $92.80 billion, a PE ratio of 20.67 and a beta of 1.17. Bristol-Myers Squibb Company has a 1-year low of $46.01 and a 1-year high of $61.30. The stock’s 50 day moving average price is $55.82 and its 200-day moving average price is $54.60.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.01. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. During the same quarter in the prior year, the company earned $0.69 earnings per share. Bristol-Myers Squibb’s revenue was up 5.6% on a year-over-year basis. On average, equities analysts predict that Bristol-Myers Squibb Company will post $2.97 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 2.76%. The ex-dividend date of this dividend was Wednesday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is 56.73%.

In other news, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction on Wednesday, August 2nd. The shares were bought at an average price of $55.94 per share, with a total value of $335,640.00. Following the completion of the acquisition, the director now owns 18,000 shares in the company, valued at $1,006,920. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.23% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.